ProNAi Therapeutics Granted Orphan Drug Designation for PNT2258 for the Treatment of Diffuse Large B-Cell Lymphoma Biotech Investing
FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 Biotech Investing
Provectus Biopharmaceuticals Changes Date of Quarterly Business Update Conference Call Biotech Investing
Histogenics Reports Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2015 Biotech Investing
Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy Biotech Investing
Avita Medical Reports Positive Results from Randomized, Multicentre EU Study of ReGenerCell™ Biotech Investing
